Your browser doesn't support javascript.
loading
Redefining osteoporosis treatment: who to treat and how long to treat / Redefinindo o tratamento da osteoporose: quem tratar e até quando
Lewiecki, E. Michael; Silverman, Stuart L.
  • Lewiecki, E. Michael; New Mexico Clinical Research and Osteoporosis Center. Albuquerque. US
  • Silverman, Stuart L; University of California. Cedars-Sinai. Los Angles. US
Arq. bras. endocrinol. metab ; 50(4): 694-704, ago. 2006.
Article in English, Portuguese | LILACS | ID: lil-437620
ABSTRACT
Osteoporosis is a common disease that is associated with increased risk of fractures and serious clinical consequences. Bone mineral density (BMD) testing is used to diagnose osteoporosis, estimate the risk of fracture, and monitor changes in BMD over time. Combining clinical risk factors for fracture with BMD is a better predictor of fracture risk than BMD or clinical risk factors alone. Methodologies are being developed to use BMD and validated risk factors to estimate the 10-year probability of fracture, and then combine fracture probability with country-specific economic assumptions to determine cost-effective intervention thresholds. The decision to treat is based on factors that also include availability of therapy, patient preferences, and co-morbidities. All patients benefit from nonpharmacological lifestyle treatments such a weight-bearing exercise, adequate intake of calcium and vitamin D, fall prevention, avoidance of cigarette smoking and bone-toxic drugs, and moderation of alcohol intake. Patients at high risk for fracture should be considered for pharmacological therapy, which can reduce fracture risk by about 50 percent.
RESUMO
Osteoporose é uma doença comum, que está associada a um aumento do risco de fraturas e de importantes conseqüências clínicas. A densidade mineral óssea (DMO) é o método usado para o diagnóstico da osteoporose, estimando o risco de fratura e monitorando as alterações da DMO durante o tempo. A combinação de fatores de risco para fraturas com a densidade mineral óssea é melhor preditor do risco de fratura do que um deles isoladamente. Metodologias estão sendo desenvolvidas para usar a DMO e fatores de risco validados para estimar o risco de fraturas em 10 anos. A decisão de tratar também está baseada em fatores que incluem terapia disponível, preferência do paciente e co-morbidades. Todos os pacientes se beneficiam de medidas não farmacológicas tais como uma ingesta adequada de cálcio e vitamina D, prevenção de queda, evitar tabagismo e drogas de efeito tóxico ao osso. Pacientes de alto risco de fraturas devem ser considerados para o tratamento farmacológico, os quais podem reduzir este risco em 50 por cento.
Subject(s)
Full text: Available Index: LILACS (Americas) Main subject: Osteoporosis / Bone Density / Diphosphonates / Fractures, Bone / Bone Density Conservation Agents Type of study: Etiology study / Prognostic study / Risk factors Limits: Adult / Female / Humans / Male Language: English / Portuguese Journal: Arq. bras. endocrinol. metab Journal subject: Endocrinology / Metabolism Year: 2006 Type: Article Affiliation country: United States Institution/Affiliation country: New Mexico Clinical Research and Osteoporosis Center/US / University of California/US

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Osteoporosis / Bone Density / Diphosphonates / Fractures, Bone / Bone Density Conservation Agents Type of study: Etiology study / Prognostic study / Risk factors Limits: Adult / Female / Humans / Male Language: English / Portuguese Journal: Arq. bras. endocrinol. metab Journal subject: Endocrinology / Metabolism Year: 2006 Type: Article Affiliation country: United States Institution/Affiliation country: New Mexico Clinical Research and Osteoporosis Center/US / University of California/US